Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A new subgroup analysis from the CLEAR Outcomes trial shows that bempedoic acid — a cholesterol-lowering drug for statin-intolerant patients — reduced major adverse limb events (MALE) by 36% in those with peripheral artery disease (PAD). Notably, the benefit appeared even in patients with no prior limb events. Experts say the findings reinforce that PAD is a high-risk form of ASCVD deserving more aggressive lipid-lowering treatment.
A new subgroup analysis from the CLEAR Outcomes trial is making the case that bempedoic acid (Nexletol) deserves a bigger role in managing peripheral artery disease (PAD). Among the 1,624 statin-intolerant PAD patients in the trial, those on bempedoic acid saw a 36% lower risk of major adverse limb events (MALE) and 45% fewer total MALE compared to placebo — with benefits emerging as early as 6 months into treatment.
What's especially notable: nearly three-quarters of PAD patients in the study had no prior limb events, yet the drug still delivered meaningful protection. Experts say this underscores that ASCVD — including PAD — exists on a spectrum of risk, and that lipid-lowering therapy should be applied broadly across that spectrum. Commentators also flagged that PAD remains underdiagnosed and undertreated relative to coronary artery disease, making these findings a call to action for closing guideline implementation gaps.
Key Takeaways:
Why it matters: PAD patients face high rates of limb complications and cardiovascular events, yet they've historically received less aggressive lipid-lowering care than those with coronary artery disease. These findings, aligned with the 2026 ACC/AHA dyslipidemia guidelines, give clinicians stronger evidence to treat PAD patients with nonstatin therapies when statins aren't tolerated.
